Open-field test
Injections (subcutaneous semaglutide or tirzepatide) are the established, clinically studied route with predictable blood levels and robust weight-loss outcomes
Patients should also contact their provider if they experience hypoglycemia (blood glucose below 70 mg/dL) or severe hypoglycemia (below 54 mg/dL), particularly if taking insulin or sulfonylureas
Providers like Fella Health offer comprehensive plans with coaching, while others focus on affordability or simple access to medication
The primary outcome being assessed is the time until the occurrence of the first cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina pectoris
Identification, genomic organization, and oxidative stress response of a sigma class glutathione S-transferase gene (AccGSTS1) in the honey bee, Apis cerana cerana